Search

everythinglearnresearchcommunity

for

Search:↓

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Gefitinib can cause hair and eyebrow darkening.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Gefitinib can cause rare scarring hair loss.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Tofacitinib might be used to treat hair loss.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Gefitinib can cause hair loss without scarring.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Nilotinib can cause keratosis pilaris, a skin condition.